|
Jul 13
|
Moderna, Inc. (NASDAQ:MRNA) is favoured by institutional owners who hold 68% of the company
|
|
Jun 22
|
Insiders At Moderna Sold US$3.3m In Stock, Alluding To Potential Weakness
|
|
Jun 3
|
FDA considers updating COVID boosters, Novavax stock reacts
|
|
Jun 3
|
Moderna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in Recurrence-Free Survival & Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stage...
|
|
May 31
|
Moderna Looks for Boost From Newly Approved RSV Shot
|
|
May 31
|
Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)
|
|
Mar 27
|
Moderna CEO discusses China investment, expanding vaccines
|
|
Mar 27
|
Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials
|
|
Mar 26
|
Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine
|